Introduction
Percutaneous mitral valve repair (PMVR) using the MitraClip™ system (Abbott Vascular Devices, Santa Clara, CA, USA) has been established as a suitable alternative to mitral valve surgery in patients with severe mitral regurgitation (MR) and high or prohibitive surgical risk.
1 -3 The EVEREST II trial mainly focused on degenerative MR and patients with preserved left ventricular ejection fraction (LVEF 60.0 ± 10.1%). To date, only a few studies with limited patient numbers (mainly single-centre reports) have been published focusing on patients with severely reduced left ventricular (LV) function. 4 -11 Of those reports, only Lesevic et al. 5 and Bozdag-Turan et al. 6 compared the outcome of patients with severely reduced LVEF (≤30%) with patients with LVEF >30%. No significant differences concerning MR reduction, functional improvement [New York Heart Association (NYHA) class improvement], and mortality rate were observed in either study at a median follow-up of 12 months, implying feasibility of PMVR using the MitraClip™ device in this critically ill patient population. However, patient number was small in both studies with only 42 and 39 subjects presenting with LVEF ≤30% pre-interventionally. Thus, in the present study-analysing data of 777 patients of the German mitral valve registry-we investigated safety, efficacy, and 1-year outcome of percutaneous MitraClip™ implantation in severe heart failure patients in comparison to patients with preserved or only moderately reduced LV function, respectively.
Methods

The German mitral valve registry
The German multicentre TRAnscatheter Mitral valve Interventions (TRAMI) registry was established in August 2010 and aims to evaluate safety and efficacy of PMVR using the MitraClip™ system in daily clinical practice. Currently, 21 German centres are participating in this investigator-initiated registry. It is open to all German sites performing percutaneous mitral valve interventions and all patients undergoing MitraClip™ implantation are eligible for enrolment. The registry comprises a retrospective section amenable for patients being treated before the individual study site has been initiated and a prospective section scheduling follow-up visits at 30 days, 1, 3, and 5 years after the procedure. Data were collected by the Institut für Herzinfarktforschung (IHF) at the Heart Centre Ludwigshafen using an internet-based standardized electronic case report form. All patients provided informed written consent and institutional review board approval was obtained for each centre. The study complies with the ethical standards of the Declaration of Helsinki. Further details of the TRAMI registry have recently been described. 12 -14 
Patient population
For the present analysis, only data from the prospective section of the TRAMI registry were included. From 1st August 2010 until 1st August 2013, 777 patients were enrolled. Follow-up was organized by the IHF, performed by a structured telephone interview and evaluated up to 1 year after MitraClip™ procedures. Patients were separated into three groups according to cardiac ejection fraction (EF <30%, 30-50% and >50%), assessed at baseline. 
Definitions and echocardiographic assessment
Assessment of echocardiographic parameters, including MR severity and LVEF, was performed at the participating study sites according to current recommendations. 15 Procedural success was defined as placement of one or more MitraClips™ resulting in MR ≤2+. MACCE was defined as major adverse cardiac or cardiovascular events including death of all causes, stroke, and myocardial infarction. Intraprocedural complications were not clearly defined and reported at the interventionalist's discretion.
Statistics
All statistical analyses were performed independently at the IHF. Categorical variables are presented by absolute numbers and percentages and are compared by 2 test. Continuous variables are expressed as mean values with standard deviations or medians with interquartile ranges (IQR) and are compared by the Kruskal-Wallis test. One-year mortality rates as well as 1-year MACCE rates were estimated by the Kaplan-Meier method applying a log-rank test. Multivariable Cox regression using stepwise forward selection was used to analyse the influence of LVEF on 1-year outcomes (mortality, MACCE, rehospitalization). According to previously published analyses of the TRAMI registry 14 the model was adjusted to 15 baseline and procedural characteristics (EF, age >75 years, female gender, NYHA class IV, sinus rhythm, anaemia, number of implanted clips ≥2, previous aortic valve intervention, creatinine ≥1.5 mg/dL, peripheral artery disease, chronic obstructive pulmonary disease, previous cardiac decompensation, previous stroke, severe tricuspid regurgitation, and procedural failure), including EF, age >75 years, and gender as fixed effects. To avoid redundancies, surgical risk scores were not inserted into the model. To identify the influence of the aforementioned variables on 1-year mortality in the three EF groups a multivariable Cox regression was used, including effects that proved to be statistically significant in univariable analysis as well as the covariates 'gender' and 'age >75 years'.
All tests were two-tailed and a P-value of <0.05 was considered significant. For statistical analysis, SAS statistical package version 9.3 (SAS, Cary, NC, USA) was used.
Results
Patient characteristics
Among 777 MitraClip™ implantations included in the TRAMI registry, we identified 256 patients (33.0%) suffering from severely reduced systolic LV function (EF <30%). Two hundred and forty-one patients (31.0%) presented with preserved systolic LV function (EF >50%) and in 280 patients (36.0%) EF was 30-50% prior to PMVR. A detailed overview of patients' baseline characteristics according to LVEF is shown in at least a cardiologist and a cardiac surgeon in the majority of cases in all groups.
Procedural details and in-hospital outcomes
A detailed overview of procedural data and in-hospital outcomes according to LVEF is shown in Table 2 . Acute procedural success rates (post-procedural MR ≤2+) were high in all groups with no statistically significant differences in residual MR at the end of the procedure [LVEF <30%, 98.8% (251/254); LVEF 30-50%, 97.5% (272/279); LVEF >50%, 95.9% (231/241); P = 0.11], remaining largely unchanged at discharge. In patients presenting with reduced LV function a higher number of clips per procedure was implanted with decreasing LVEF (LVEF <30%, 1.5 ± 1.6; LVEF 30-50%, 1.5 ± 1.6; LVEF >50%, 1.3 ± 0.6; P < 0. <30%, 32.9 ± 64.8 min; LVEF 30-50%, 30.4 ± 74.0 min; LVEF >50%, 24.5 ± 17.3 min; P < 0.05). Nevertheless, procedure times were comparable among groups. Periprocedural complication rates were low throughout all groups with no event in patients presenting with severely impaired LV function.
In-hospital mortality rates were low and comparable in all groups [LVEF <30%, 3.1% (8/256), LVEF 30-50%, 2.1% (6/280); LVEF >50%, 1.7% (4/240); P = 0.54].
In-hospital MACCE rates did not differ between groups [LVEF <30%, 3.2% (8/253); LVEF 30-50%, 2.9% (8/272); LVEF >50%, 2.5% (6/236); P = 0.92].
Neither duration of intensive care unit (ICU) stay [LVEF <30%, Clinical benefit of patients with severely impaired LV function was comparable to the other patient groups according to NYHA functional class (Figure 3) . Thus, 69.5% of patients presenting with LVEF <30% prior to PMVR showed an improvement by one or more NYHA functional classes. Compared with patients with preserved LV function (LVEF >50%), this is a significantly larger proportion (LVEF >50%: 56.8%; P < 0.05). Additionally, a relevant, although statistically insignificant, improvement in mobility, ability to take care of oneself, and activities of daily life were achieved in patients with severely reduced LV function. Thus, the rate of bed-ridden patients declined from 7.0% before to 1.3% 1 year after MitraClip™ implantation and 47.0% (vs. 31.2% prior to PMVR) of severe heart failure patients were able to perform activities of daily life without restrictions. In line with these observations, 48.7% of patients presenting with LVEF <30% prior to PMVR reported an improvement of their health status 1 year after the procedure. One-year results of patients presenting with secondary MR are shown in Table 4 .
Patients with secondary mitral regurgitation
Predictors of 1-year mortality
Baseline and procedural characteristics were compared between survivors and non-survivors at 1 year in order to identify risk factors for long-term mortality.
Analysis of the overall TRAMI population-recently published by Puls et al.
14 -revealed LVEF <30% (HR 1.58, P = 0.01) to be an independent predictor of 1-year mortality. Furthermore, NYHA 
Kaplan-Meier curves for MACCE at 1 year according to EF
Figure 2 Kaplan-Meier curves for major adverse cardiac or cardiovascular events (MACCE) at 1 year according to left ventricular ejection fraction (EF).
class IV (HR 1.62, P = 0.02), anaemia (HR 2.44, P = 0.02), previous aortic valve intervention (HR 2.12, P = 0.002), serum creatinine ≥1.5 mg/dL (HR 1.77, P = 0.002), peripheral artery disease (HR 2.12, P = 0.0003), severe tricuspid regurgitation (HR 1.84, P = 0.003), and procedural failure (defined as operator-reported failure, conversion to surgery, failure of clip placement, or residual post-procedural severe MR) (HR 4.36, P < 0.0001) were also identified as predictors of 1-year mortality when analysing the entire TRAMI population. Multivariable analysis of LVEF subgroups revealed procedural failure as the main predictor for mortality in LVEF <30% patients (HR 10.38; 95% CI 3.71-29.02). Furthermore, peripheral artery disease (HR 2.74; 1.38-5.44) was identified as a significant predictor of 1-year mortality in patients with severely reduced LV function. In patients with preserved LV function (LVEF >50%), procedural failure (HR 3.99; 1.36-11.71), peripheral artery disease (HR 3.83; 1.72-8.54), previous aortic valve intervention (HR 2.74; 1.23-6.13), and NYHA class IV (HR 2.44; 1.14-5.21) were identified as significant predictors of 1-year mortality. Anaemia (HR 4.11; 1.13-14.96) and serum creatinine ≥1.5 mg/dL (HR 3.35; 1.59-7.06) were significantly related to 1-year mortality in patients presenting with an LVEF 30-50% prior to PMVR.
An overview of predictors of 1-year mortality is shown in 
Discussion
Feasibility of PMVR using the MitraClip™ device in severe heart failure patients has been suggested by several mainly single-centre reports with limited patient numbers. 4 -11 In this study we investigated safety, efficacy, and 1-year outcome of percutaneous MitraClip™ implantation in patients with severely reduced LVEF (<30%) analysing data of the German mitral valve registry representing the largest cohort of patients undergoing PMVR with the MitraClip™ device. Results were compared with patients with preserved or only moderately decreased LV function. The main findings of our study comprise technical feasibility as well as procedural safety and clinical efficacy of MitraClip™ implantation in severe heart failure patients. Primary procedural success rates were high in all patients irrespective of LV function, achieving a significant MR reduction in 98.8% of patients with severely impaired LV function. Procedural safety was very high throughout all groups with no complications observed in severe heart failure patients. Presumably due to the fact that the percentage of patients presenting with secondary MR was significantly higher in LVEF <30% patients, a higher number of clips per procedure was implanted with decreasing LV function, resulting in longer procedural fluoroscopy times but comparable overall procedure times. Although it seems that PMVR using the MitraClip™ device in LVEF <30% patients is more complex, procedural success and residual MR after the procedure and at discharge were similar to that of patients with superior LV functions. Moreover, 1-year necessity of mitral valve re-intervention was similar between groups, implying comparable mid-term results. Most importantly, clinical benefit of patients with severely reduced LV function undergoing PMVR with the MitraClip™ device was distinctive, persistent for the 1-year follow-up period, and comparable to the effects achieved in patients with moderately reduced or preserved LV function, respectively. Thus, 67.4% of severe heart failure patients were in NYHA functional class I or II 1 year after the procedure and 69.5% of those patients had improved by one or more NYHA functional classes, interestingly representing a significantly larger proportion compared with patients with preserved LV function. In accordance with these findings, 48.7% of LVEF <30% patients reported an improved overall health status compared with the time prior to the procedure. These effects are consistent in a subgroup analysis of patients presenting with secondary MR. Reverse cardiac remodelling, including left atrial and LV volume reduction, as well as increase in LVEF has been demonstrated in several previously published studies.
4,6,8 -11 These effects were found 6-12 months after PMVR and also occurred in patients with severely decreased LV function prior to MitraClip™ implantation. Reverse cardiac remodelling might be the underlying pathomorphological correlate for the considerable symptomatic improvement also observed in our patient population.
In-hospital mortality was low and comparable in all groups. Multivariable-adjusted analysis of 1-year mortality and MACCE rates (mainly driven by death of all causes) revealed significantly more events in patients with severely impaired LV function. Considering the significantly higher logistic EuroSCORE and more pronounced co-morbidities of patients with LVEF <30% in this study, as well as the high mortality rates of severe heart failure patients in general, with up to 60-70% dying within 5 years, finding is not surprising. Thus, in a recently published analysis on 1-year outcomes of the TRAMI registry, LVEF <30% was found to be an independent predictor of mortality.
14 In accordance with our findings relating to mortality rates, Lesevic et al. 5 (35/42 vs. 85/94, P = 0.279) as well as Bozdag-Turan et al. 6 (25/38 vs. 68/83, P = 0.051) observed a trend for higher mortality rates in patients with LVEF ≤30% after a median follow up of 12 months. Due to the limited number of this severely ill patient group compared with patients with LVEF >30%, no statistically significant survival differences were revealed in those studies. Importantly, procedural failure was found to be the main predictor for mortality in LVEF <30% patients in our study (HR 10.38; 95% CI 3.71-29.02). This implies that successful PMVR using the MitraClip™ device in patients with severely reduced LV function is a meaningful therapy for improved survival.
Interestingly, contrary to the time prior to PMVR, the acute heart failure rehospitalization rates observed in our study did not significantly differ anymore within the groups after MitraClip™ implantation. Similarly, the overall rehospitalization rates showed no differences between the groups, with total time of rehospitalization days even suggesting a trend towards shorter hospital stays in patients with severely reduced LV function. These findings are in line with observations of improved mobility enabling large portions of this severely diseased patient group to take care of themselves and to participate in activities of daily life without restrictions. Thus, PMVR using the MitraClip™ device offers a safe and effective treatment option for severe heart failure patients with high-grade MR, being at high or prohibitive risk for surgical mitral valve interventions. Even in this critically ill patient population, significant symptomatic improvement with distinctive implications for daily life activities can be achieved. 
Limitations
As a post-market registry, the German mitral valve registry reflects real-world practice, leading to a very inhomogeneous patient population without predefined formal inclusion or exclusion criteria, and lack of randomization. Moreover, availability of 1-year follow-up information is limited to 90.1% of patient outcomes reported. Furthermore, no structured echocardiographic data acquisition was performed after hospital discharge and analyses were not conducted by a core lab. However, as functional MR is known to be fluctuant and load dependent, its measurement is difficult to standardize. In addition, MR grading after a double orifice repair is challenging and occasionally imprecise. Thus, MR reduction is a weak measure of the efficacy of the procedure, and functional outcomes including enhancement of quality of life are a more appropriate way of assessing the value of PMVR using the MitraClip™ device, especially in high-risk patient populations with severely reduced LV function and multiple co-morbidities suffering from secondary MR. 17 For a more thorough and valid analysis of the MitraClip™ procedure in this severely diseased patient group, two randomized clinical trials are currently recruiting patients.
Conclusion
In patients with severely reduced systolic LV function undergoing MitraClip™ therapy, procedural safety, efficacy, and clinical improvement after 1 year are comparable to patients with preserved LV function.
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